[Status of surgery in the treatment of metastatic renal cell carcinoma].
A report is presented on 78 patients with metastatic renal cell carcinoma (RCC, Robson III and IV). The average survival time was 2.1 years after nephrectomy, 1.1 years after embolization and only 0.65 years in the patients who underwent no surgery at all. As there is still not known effective systemic cytostatic therapy for this type of tumour, there is no doubt about the priority of nephrectomy. The indication for nephrectomy is limited by the feasibility of total removal of the metastases. An extension of this indication limit has not improved the survival rate. There is no difference in survival rate between patients with removable local, as opposed to operable distant metastases. In those cases where nephrectomy was not possible the patients did better after embolization than with no surgery at all.
D000368:Aged; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000601:surgery*; D004621:Embolization, Therapeutic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009392:Nephrectomy; D010166:Palliative Care
Stellenwert der Operation in der Behandlung des metastasierten Nierenzellkarzinoms.